Orion is well known world-wide for the medicines it has developed for Parkinson's disease.  Stalevo and Comtess/Comtan, which are based on the entacapone molecule discovery, are by far the brightest stars in Orion’s product portfolio.

Entacapone is a substance which enhances the effect of levodopa, the basic medication used for Parkinson's disease, by inhibiting an enzyme called COMT. Entacapone is always taken together with levodopa. Entacapone was launched in Europe in 1998, and a year later in the United States.Orion markets entacapone under the name Comtess®. In countries where Orion doesn’t have its own sales organisation, it is sold by the partner Novartis as Comtan®. Comtess/Comtan is the first major globally sold drug originated by Orion.